- Home
- AIFF vs INKT Comparison
AIFF vs INKT Comparison
Compare AIFF & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- INKT
- Stock Information
- Founded
- AIFF 2006
- INKT 2017
- Country
- AIFF United States
- INKT United States
- Employees
- AIFF N/A
- INKT N/A
- Industry
- AIFF
- INKT Medicinal Chemicals and Botanical Products
- Sector
- AIFF
- INKT Health Care
- Exchange
- AIFF NYSE
- INKT Nasdaq
- Market Cap
- AIFF 34.4M
- INKT 31.2M
- IPO Year
- AIFF N/A
- INKT 2021
- Fundamental
- Price
- AIFF $3.10
- INKT $7.03
- Analyst Decision
- AIFF
- INKT Strong Buy
- Analyst Count
- AIFF 0
- INKT 2
- Target Price
- AIFF N/A
- INKT $37.50
- AVG Volume (30 Days)
- AIFF 1.9M
- INKT 5.4K
- Earning Date
- AIFF 05-14-2025
- INKT 05-15-2025
- Dividend Yield
- AIFF N/A
- INKT N/A
- EPS Growth
- AIFF N/A
- INKT N/A
- EPS
- AIFF N/A
- INKT N/A
- Revenue
- AIFF $139,000.00
- INKT N/A
- Revenue This Year
- AIFF N/A
- INKT N/A
- Revenue Next Year
- AIFF N/A
- INKT N/A
- P/E Ratio
- AIFF N/A
- INKT N/A
- Revenue Growth
- AIFF N/A
- INKT N/A
- 52 Week Low
- AIFF $1.86
- INKT $4.56
- 52 Week High
- AIFF $17.20
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- AIFF 43.40
- INKT 44.59
- Support Level
- AIFF $3.12
- INKT $6.89
- Resistance Level
- AIFF $3.57
- INKT $7.40
- Average True Range (ATR)
- AIFF 0.21
- INKT 0.53
- MACD
- AIFF 0.01
- INKT -0.01
- Stochastic Oscillator
- AIFF 25.40
- INKT 40.59
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.